How big data can help retinal medicine
Useful conclusions have already been drawn from analyses of big data
Leigh Spielberg
Published: Friday, September 6, 2019
[caption id="attachment_16395" align="alignleft" width="1024"]
Adnan Tufail[/caption]
“What is big data? Why am I interested in big data? And why should you be interested in it?” were the three big questions that Adnan Tufail, Moorfields Eye Hospital, London, United Kingdom sought to answer in his presentation.
Entitled, “Big Data for Retina: Perspectives and Cautions,” Dr Tufail’s presentation was given to delegates at the 19th Annual EURETINA Congress in Paris yesterday morning.
Dr Tufail’s interest in big data originated with the discrepancies that he had noticed between clinical trial results and real-world outcomes regarding anti-VEGF treatments. “Within two months, we had generated a database of more than 11,000 eyes,” he said.
“Ironically, large data sets may help with precision medicine, meaning: what can an individual patient expect from a certain treatment?” said Dr Tufail.
So why should ophthalmologists be interested? Because very useful conclusions have already been drawn from analyses of big data. Diabetic retinopathy progression can be predicted based on the baseline retinopathy and clinical features; a history of intravitreal injections is a significant predictor of posterior capsular rupture during cataract surgery; and software currently exists that can accurately distinguish age-related macular degeneration from normal eyes based on OCT. Big data is coming.
Adnan Tufail[/caption]
“What is big data? Why am I interested in big data? And why should you be interested in it?” were the three big questions that Adnan Tufail, Moorfields Eye Hospital, London, United Kingdom sought to answer in his presentation.
Entitled, “Big Data for Retina: Perspectives and Cautions,” Dr Tufail’s presentation was given to delegates at the 19th Annual EURETINA Congress in Paris yesterday morning.
Dr Tufail’s interest in big data originated with the discrepancies that he had noticed between clinical trial results and real-world outcomes regarding anti-VEGF treatments. “Within two months, we had generated a database of more than 11,000 eyes,” he said.
“Ironically, large data sets may help with precision medicine, meaning: what can an individual patient expect from a certain treatment?” said Dr Tufail.
So why should ophthalmologists be interested? Because very useful conclusions have already been drawn from analyses of big data. Diabetic retinopathy progression can be predicted based on the baseline retinopathy and clinical features; a history of intravitreal injections is a significant predictor of posterior capsular rupture during cataract surgery; and software currently exists that can accurately distinguish age-related macular degeneration from normal eyes based on OCT. Big data is coming.
Tags: anti-VEGF, big data, diabetic retinopathy, intravitreal injections
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.